We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the Sept. 7 issue, “FDA Panel Recommends Folotyn, Wants New Romidepsin Study” stated the Oncologic Drugs Advisory Committee voted 7–3 to “recommend further study of romidepsin.” The panel voted to recommend randomized studies in future development of drugs to treat cutaneous T-cell lymphoma (CTCL), but did not vote to recommend additional studies for Gloucester Pharmaceutical’s Istodax (romidepsin). The company and the FDA had agreed on a special protocol assessment that did not include a randomized study and, as the article states, the panel voted 10–0 that results of Istodax’s two single-arm trials represent a favorable risk-benefit profile for patients with CTCL.